The weekly litigation news digest is live. Subscribe now

IP Verse

Pharmaceutical Composition Containing Rifaximin Alpha & Delta - EP3434265

The patent EP3434265 was granted to Sandoz on Jul 7, 2021. The application was filed on Mar 22, 2017 under application number EP18193241A. The patent is currently recorded with a legal status of "Revoked".

EP3434265

SANDOZ
Application Number
EP18193241A
Filing Date
Mar 22, 2017
Status
Revoked
May 24, 2024
Publication Date
Jul 7, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
TEVA PHARMACEUTICALSApr 7, 2022D YOUNGADMISSIBLE
ALFRED E TIEFENBACHERApr 6, 2022HAMM & WITTKOPPADMISSIBLE
ALFASIGMAMar 21, 2022KRAUS & LEDERER PARTGMBBADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
OPPOSITIONEP1557421
OPPOSITIONEP1698630
OPPOSITIONEP2927235
OPPOSITIONEP3294270
OPPOSITIONEP3373914
OPPOSITIONWO2005044823
OPPOSITIONWO2011107970
SEARCHEP1698630
SEARCHUS9018225

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents